Shares of Divi’s Laboratories jumped 3% after the company announced a long-term manufacturing and supply agreement with a leading global pharmaceutical firm. As of 9:18 AM, the shares were trading 3.59% higher at Rs 6,715.50.
This strategic move boosts Divi’s presence in the custom synthesis segment, reinforcing its position as a trusted contract manufacturing partner on the international stage.
Under the deal, Divi’s will manufacture and supply advanced pharmaceutical intermediates, a high-value segment that is expected to significantly enhance the company’s revenue over the duration of the contract. Although the partner’s identity and financial specifics remain under wraps due to a non-disclosure agreement, the company has indicated that the expected returns are substantial.
To meet the growing demand, Divi’s Laboratories is planning a capacity expansion investment of ₹650–750 crore, which will be funded through a phased capacity reservation advance from the customer. This ensures financial stability while scaling operations.
The company clarified that the agreement is entirely commercial with no related party involvement, highlighting its commitment to transparency and global business standards.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information
